首页> 外文期刊>Molecular Metabolism >Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease
【24h】

Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease

机译:肝细胞miR-34a是非酒精脂肪肝病的开发和进展中的关键调节因素

获取原文
           

摘要

Objective Hepatic miR-34a expression is elevated in diet-induced or genetically obese mice and patients with non-alcoholic steatohepatitis (NASH), yet hepatocyte miR-34a's role in the progression of non-alcoholic fatty liver disease (NAFLD) from non-alcoholic fatty liver (NAFL) to NASH remains to be elucidated. Methods Mice overexpressing or deficient in hepatocyte miR-34a and control mice were fed a diet enriched in fats, cholesterol, and fructose (HFCF) to induce NASH. C57BL/6 mice with NASH were treated with an miR-34a inhibitor or a scramble control oligo. The effect of miR-34a on the development, progression, and reversal of NAFLD was determined. Results The hepatocyte-specific expression of miR-34a aggravated HFCF diet-induced NAFLD. In contrast, germline or adult-onset deletion of hepatocyte miR-34a attenuated the development and progression of NAFLD. In addition, pharmacological inhibition of miR-34a reversed HFCF diet-induced steatohepatitis. Mechanistically, hepatocyte miR-34a regulated the development and progression of NAFLD by inducing lipid absorption, lipogenesis, inflammation, and apoptosis but inhibiting fatty acid oxidation. Conclusions Hepatocyte miR-34a is an important regulator in the development and progression of NAFLD. MiR-34a may be a useful target for treating NAFLD.
机译:目的肝miR-34a表达在饮食诱导或遗传肥胖的小鼠和非酒精脂肪性肝炎(NASH)患者中升高,肝细胞miR-34a在非酒精性脂肪肝病(NAFLD)中的作用中的作用脂肪肝(NAFL)纳什仍有待阐明。方法对肝细胞miR-34a和对照小鼠的过表达或缺乏的小鼠喂养富含脂肪,胆固醇和果糖(HFCF)的饮食以诱导肿瘤。用miR-34a抑制剂或争夺控制寡核苷酸处理C57BL / 6小鼠。 MIR-34A对NAFLD的开发,进展和逆转的影响。结果MIR-34A的肝细胞特异性表达加重HFCF饮食诱导的NAFLD。相比之下,肝细胞miR-34a的种系或成人发作缺失衰减了Nafld的发育和进展。此外,MiR-34A的药理抑制反转HFCF饮食诱导的胫骨肝炎。机械上,肝细胞miR-34a通过诱导脂质吸收,脂肪生成,炎症和凋亡而抑制脂肪酸氧化,调节NAFLD的开发和进展。结论肝细胞miR-34a是NAFLD开发和进展的重要调节因素。 miR-34a可以是治疗nafld的有用靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号